[Form 4] PROCEPT BioRobotics Corporation Insider Trading Activity
Rhea-AI Filing Summary
The filing shows that Antal Rohit Desai, a director of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 26,749 shares on 08/14/2025 at a cash exercise price of $1.33 per share. After the transaction he beneficially owns 35,152 shares in total, including 14,363 shares held indirectly by The 2:22 DNA Trust. The option exercised was fully vested and exercisable, and the exercise was executed for cash. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Desai on 08/15/2025.
Positive
- Director increased ownership by exercising 26,749 options, raising beneficial holdings to 35,152 shares.
- Options were fully vested and exercisable, and the exercise was completed as a cash transaction at $1.33 per share.
Negative
- None.
Insights
TL;DR: Director exercised fully vested options to acquire 26,749 shares at $1.33, modestly increasing insider ownership.
The transaction is a routine insider option exercise rather than an open-market purchase or sale. A cash exercise of 26,749 options increases total reported beneficial ownership to 35,152 shares, with 14,363 shares held indirectly through a trust. For investors this is a limited, non-dilutive transfer from option to common stock that does not change company cash flow materially beyond the exercise proceeds.
TL;DR: This Form 4 documents a standard, fully vested option exercise by a director; disclosure appears complete and timely.
The filing identifies the reporter as a director and indicates the option was fully vested and exercised for cash. Reporting was done on a single-person Form 4 and signed by an attorney-in-fact. No additional derivative holdings remain for the reporter post-transaction. From a governance and disclosure standpoint, the Form 4 provides the required details: dates, quantities, price, and ownership form.